AI-Driven Retinal Screening Device Market Report 2026

The artificial intelligence (AI)-driven retinal screening device market size has grown rapidly in recent years. It will grow from $1.93 billion in 2025 to $2.18 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to increasing adoption of artificial intelligence (AI)-enabled ophthalmic diagnostics, growing incidence of diabetic retinopathy, rising demand for early retinal disease detection, increasing integration of digital health screening programs, and growing healthcare focus on preventive eye care.

The artificial intelligence (AI)-driven retinal screening device market size is expected to see rapid growth in the next few years. It will grow to $3.54 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to growing use of autonomous artificial intelligence (AI)-based screening systems, increasing deployment of point-of-care retinal devices, rising government support for digital eye screening initiatives, expanding integration of artificial intelligence (AI) tools in teleophthalmology, and increasing demand for rapid and low-cost retinal assessment solutions. Major trends in the forecast period include advancements in artificial intelligence (AI) algorithms for retinal image interpretation, innovations in edge-computing retinal screening devices, technology developments improving image acquisition quality, research and development in multimodal eye-disease detection platforms, and advancements in cloud-based artificial intelligence (AI) screening workflows.

The growing burden of diabetes is expected to propel the growth of the AI-driven retinal screening device market going forward. Diabetes is a chronic metabolic disease characterized by persistently high blood glucose levels that damage blood vessels over time, including those supplying the retina, and it is a leading cause of preventable vision loss worldwide. The rise in the diabetes burden is due to aging populations and lifestyle changes, which have increased obesity rates and reduced physical activity across both developed and developing regions. AI-driven retinal screening devices help in managing diabetes by enabling early detection of diabetes-related retinal damage, expanding screening access at scale, and supporting timely clinical intervention to prevent vision impairment. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based global health organization, approximately 589 million adults aged 20-79 were living with diabetes worldwide in 2024, with projections indicating that this number could rise to 853 million by 2050, showing a significant increase compared to previous decades. Therefore, the growing global burden of diabetes is driving the growth of the AI-driven retinal screening device market.

Leading companies operating in the artificial intelligence (AI)-driven retinal screening device market are focusing on developing advanced products, such as handheld AI fundus cameras, to boost accessibility, enhance diagnostic speed, and enable earlier disease detection. Handheld AI fundus cameras refer to portable imaging devices that use artificial intelligence to automatically analyze images of the retina for signs of disease. For instance, in May 2024, Optomed USA Inc., a US-based medical technology company, launched the Optomed Aurora AEYE. It is the first FDA-cleared, handheld AI fundus camera for the detection of more than mild diabetic retinopathy. The device features automatic, AI-based image analysis that provides an immediate screening result at the point of care, enabling clinical decision support without the need for a specialist to be present. It is battery-operated and highly portable, designed to increase access to sight-saving screenings in primary care, endocrinology, and other non-specialist settings.

In November 2025, Optain Health, a US-based healthcare technology company, acquired EyePACS for an undisclosed amount. This acquisition allows Optain Health to expand access to next-generation retinal imaging and AI-driven automated disease detection in primary care by integrating EyePACS’s extensive teleophthalmology network with its AI-enabled imaging and screening technology, thereby enhancing early detection of ocular and systemic conditions at scale. EyePACS is a US-based healthcare technology company focused on AI-driven retinal screening and teleophthalmology solutions for early detection of eye diseases.

Major companies operating in the artificial intelligence (AI)-driven retinal screening device market are Carl Zeiss Meditec AG, Topcon Corporation, Canon Medical Systems Corporation, Bosch Healthcare Solutions GmbH, Heidelberg Engineering GmbH, Shenzhen Sibionics Technology Co. Ltd., Digital Diagnostics Inc., Optomed Plc, Optain Health Inc., NIDEK Co. Ltd., Airdoc Technology Co. Ltd., Identifeye Health Ltd., Kowa Company Ltd., RetinaLyze System A/S, EyRIS Pte. Ltd., Eyenuk Inc., EYRIS Pte. Ltd., VUNO Inc., Eyenuk Inc., AEYE Health Inc.

North America was the largest region in the artificial intelligence (AI)-driven retinal screening device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven retinal screening device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI)-driven retinal screening device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have impacted the ai-driven retinal screening device market by increasing the cost of importing high-precision imaging hardware and ai software components, creating delays in deployment, particularly in regions such as north america and europe which rely on imported devices. ophthalmology clinics, hospitals, and diagnostic centers are most affected, while the tariff has encouraged local manufacturing initiatives and innovation in cost-efficient ai solutions, providing a potential positive impact on domestic production capabilities.

An artificial intelligence (AI)-driven retinal screening device is a medical diagnostic system that integrates retinal imaging hardware with AI algorithms to automatically evaluate eye images and detect signs of retinal diseases. It facilitates early, accurate, and scalable identification of eye conditions, supporting timely clinical intervention and better patient outcomes.

The main components of AI-driven retinal screening devices are hardware, software, and services. Hardware includes retinal imaging devices such as fundus cameras and optical coherence tomography systems integrated with computing modules for image capture and analysis. Technologies used include fundus image-based AI, OCT-based AI, multimodal AI, machine learning, deep learning, and natural language processing. These solutions are deployed via cloud-based and on-premises models and applied in detecting diabetic retinopathy, age-related macular degeneration, glaucoma, cataract, and other conditions, serving hospitals, ophthalmology clinics, mobile clinics or rural camps, diagnostic centers, academic institutions, and telemedicine providers.

The artificial intelligence (AI)-driven retinal screening device market consists of revenues earned by entities by providing services such as automated retinal image analysis, diabetic retinopathy screening, glaucoma risk assessment, age-related macular degeneration detection, and tele-ophthalmology screening support. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-driven retinal screening device market also includes sales of retinal imaging cameras, artificial intelligence software platforms, cloud-based diagnostic tools, handheld fundus imaging devices, and integrated screening systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.